Comparable stake leader
Brio Capital Master Fund Ltd.
SEC ownership of Sigyn Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001642159.
Disclosed value leader
Brio Capital Master Fund Ltd.
Comparable rows
1/1
Latest evidence
31 Dec 2025
- Public ticker
- SIGY on OTC
- Parsed ownership sources
-
13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Brio Capital Master Fund Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 1
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Brio Capital Master Fund Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001642159
- Issuer location
- Beverly Hills, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Sigyn Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Brio Capital Master Fund ...
Disclosed value leader
Brio Capital Master Fund ...
Comparable rows
1/1
Latest evidence
31 Dec 2025
13D/G
Lead comparable stake: 10%
13D/G row: Brio Capital Master Fund Ltd.
Quick read
Brio Capital Master Fund Ltd. leads the comparable SEC ownership view at 10%.
1 of 1 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Brio Capital Master Fund Ltd.'s linked filing trail.
Comparable ownership
Top 1
Brio Capital Master Fund Ltd.
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-1 of 1 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Brio Capital Master Fund Ltd. |
13D/G
|
10%
|
$321,074
160,537 shares
|
+$3,210 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Recent insider transactions for Sigyn Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.